Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
**Narrative Review**

**Surveillance and Monitoring of Hepatocellular Carcinoma During the COVID-19 Pandemic**

Neil Mehta,*,a Neehar D. Parikh,‡,a R. Katie Kelley,§ Bilal Hameed,*,b and Amit G. Singal,†,b

*Division of Gastroenterology, University of California, San Francisco, San Francisco, California; ‡Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan; §Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California; and †Division of Digestive and Liver Disease, UT Southwestern Medical Center, Dallas, Texas

The Coronavirus disease 2019 (COVID-19) pandemic is expected to have a long-lasting impact on the approach to care for patients at risk for and with hepatocellular carcinoma (HCC) due to the risks from potential exposure and resource reallocation. The goal of this document is to provide recommendations on HCC surveillance and monitoring, including strategies to limit unnecessary exposure while continuing to provide high-quality care for patients. Publications and guidelines pertaining to the management of HCC during COVID-19 were reviewed for recommendations related to surveillance and monitoring practices, and any available guidance was referenced to support the authors’ recommendations when applicable. Existing HCC risk stratification models should be utilized to prioritize imaging resources to those patients at highest risk of incident HCC and recurrence following therapy though surveillance can likely continue as before in settings where COVID-19 prevalence is low and adequate protections are in place. Waitlisted patients who will benefit from urgent LT should be prioritized for surveillance whereas it would be reasonable to extend surveillance interval by a short period in HCC patients with lower risk tumor features and those more than 2 years since their last treatment. For patients eligible for systemic therapy, the treatment regimen should be dictated by the risk of COVID-19 associated with route of administration, monitoring and treatment of adverse events, within the context of relative treatment efficacy.

Keywords: HCC; Screening; Alpha-Fetoprotein; AFP; Coronavirus.

The coronavirus disease 2019 (COVID-19) pandemic continues to spread worldwide, with over 5.5 million confirmed cases and over 350,000 deaths. The surge of the pandemic has overwhelmed many health systems, leading to difficult decisions about clinical resource allocation. In response, many providers and health systems have restricted in-person encounters—including radiological imaging—and utilized telehealth visits to reduce exposure for both patients and providers. COVID-related risks may be especially relevant in patients with cirrhosis and hepatocellular carcinoma (HCC), for whom management often involves multiple interactions with the health care system (eg, phlebotomy, radiological imaging, clinic visits, and HCC-directed treatments) but who may be more susceptible to severe COVID-related complications.

The COVID-19 pandemic is expected to have a long-lasting impact on the approach to care for all patients, including those with cirrhosis and HCC. Many experts have predicted the need for social distancing and other precautions for at least the next 18-24 months. Even if COVID-19 transmission is drastically reduced or eliminated in the immediate future, recurrent outbreaks could occur over the next several years. Therefore, the approach to HCC surveillance in patients with chronic hepatitis B virus (HBV) or cirrhosis, as well as HCC monitoring in those with HCC, with respect to resource allocation and disease management not only is a critical issue now, but also will potentially affect care delivery over several years. The goal of this document is to provide recommendations on HCC surveillance and monitoring during COVID-19, including strategies to limit unnecessary exposure while continuing to provide high-quality care for patients at risk for and with HCC. In settings in which COVID-19 prevalence is low and adequate protections are in place, surveillance and monitoring can likely continue as before though these recommendations can be considered as needed.

*Authors share co-first authorship. ‡Authors share co-senior authorship.

Abbreviations used in this paper: AFP, alpha-fetoprotein; COVID-19, coronavirus disease 2019; cTACE, conventional transarterial chemoembolization; CTP, Child-Turcotte-Pugh; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; LRT, local-regional therapy; LT, liver transplantation; MELD, Model for End-Stage Liver Disease; NASH, nonalcoholic steatohepatitis; SBRT, stereotactic body radiotherapy.

Most current article

© 2021 by the AGA Institute
1542-3565/$36.00
https://doi.org/10.1016/j.cgh.2020.06.072
Materials and Methods

A targeted literature search was performed to identify PubMed-referenced publications pertaining to management of hepatocellular carcinoma in the setting of the COVID-19 pandemic as of May 6, 2020. A manual search of professional society websites identified existing guidelines as of the same date. These publications and guidelines were reviewed for recommendations related to surveillance and monitoring practices, and any available guidance was referenced to support the authors’ recommendations when applicable. The management considerations presented in this summary document were circulated for review to the multidisciplinary tumor board membership at the authors’ respective institutions for input and represent a consensus opinion.

HCC Surveillance In At-Risk Patients

Professional society guidelines recommend semiannual HCC surveillance using abdominal ultrasound, with or without alpha-fetoprotein (AFP), in high-risk individuals. This practice has been associated with increased early detection and improved survival in a large randomized controlled trial among HBV patients and several cohort studies in patients with cirrhosis.

However, during the outbreak of the COVID-19 pandemic, most health systems deferred elective imaging, including HCC surveillance. In patients with COVID-19 infection, HCC surveillance should be deferred until recovery. In addition to concerns about persistent risk of COVID-19 exposure complicating re-opening of health systems, backlogs of patients waiting for deferred imaging may complicate availability of HCC surveillance imaging. Prioritizing HCC surveillance for those who derive the greatest benefit may be necessary; however, it may not be readily apparent how to best select these patients and the optimal surveillance strategies if ultrasound-based surveillance is not available.

HCC Risk Stratification Models

Although surveillance is recommended in high-risk subgroups of patients with chronic HBV and all patients with cirrhosis, risk varies between patients and risk stratification models may be used to identify those with the highest HCC incidence. There are risk stratification models both among HBV patients, of which some have been validated in both Eastern and Western populations and cirrhosis patients, predominantly derived in Western populations. To date, there has been limited validation of most models, so their clinical utility in routine practice has remained limited. However, in a restricted resource environment, components of these stratification systems could be used to identify patients who can be prioritized for surveillance and those who may be deferred.

Older age and male gender are consistent components of HCC risk stratification models. Child-Turcotte-Pugh (CTP) score and presence of portal hypertension are other important risk factors for HCC; however, this must be balanced with likely increased susceptibility to COVID-19 in those with advanced liver dysfunction. Finally, liver disease etiology is a consistent risk factor, with active viremia associated with a 3%-6% annual risk, whereas patients with nonalcoholic steatohepatitis (NASH), alcohol-related liver disease, or hepatitis C virus (HCV) cirrhosis after viral cure have a lower annual risk of 1%-2%. Patients with combinations of high risk features may be considered as the highest priority for surveillance receipt, whereas surveillance may be deferred in those with 1 or no risk factors.

HCC Surveillance in Selected Populations

Continued careful patient selection is critical, including not ordering HCC surveillance in patients unlikely to benefit. Patients with CTP C cirrhosis who are not transplant eligible are not recommended to undergo surveillance because of the competing risk of liver-related mortality. Similarly, patients with other significant comorbidities (eg, cardiovascular disease, malignancies) that limit life expectancy or treatment eligibility should not undergo surveillance. Surveillance should also not be performed in certain subgroups at lower risk (eg, HCV or NASH patients) in absence of cirrhosis, given marginal risk-benefit ratio. Preventing oversurveillance in populations unlikely to benefit is a practical way to minimize harms of surveillance, including possible COVID-19 exposure.

On the other hand, while some transplant centers have suspended or limited transplants to those with high Model for End-Stage Liver Disease (MELD) scores, the listed population could be considered a priority for surveillance receipt. Early detection (eg, within Milan criteria) is critical in this population to prevent waitlist dropout, and timely identification of HCC lesions allows patients to accrue waiting time with MELD exception. Additionally, surveillance can provide other information relevant to transplant decision making, such as development of portal vein thrombosis. Therefore, while some deferrals of HCC surveillance may be necessary in the setting of a local COVID-19 outbreak, listed patients should likely be prioritized to receive surveillance as available.

Timing of HCC Surveillance in At-Risk Patients

As recommended by AASLD and EASL, deferring HCC surveillance by 2-3 months during times of limited radiologic capacity, such as those experienced during the COVID-19 pandemic, is likely safe. Recommendations to perform semiannual surveillance were initially based on
tumor doubling time from older studies demonstrating tumor doubling times of 4–6 months. These data have since been replicated in contemporary cohort studies, although a meta-analysis suggests potential shorter doubling times in HBV-predominant populations.\textsuperscript{14,15} A large randomized controlled trial from France demonstrated that quarterly surveillance does not improve early HCC detection compared with semiannual.\textsuperscript{16} Although there is not a similar randomized controlled trial evaluating longer intervals, retrospective cohort studies have shown that semiannual surveillance results in increased early detection and improved survival compared with annual surveillance, after adjusting for lead time bias.\textsuperscript{17} However, the difference in survival benefit between the 2 intervals appears small, and both significantly improve survival compared with no surveillance. There are also no data comparing semiannual surveillance with intermediate length surveillance intervals between 8 and 10 months. Deferring HCC surveillance over short periods of time, as needed, is likely acceptable in light of an annual HCC incidence of 2%–3%, suggesting that ~98% of patients will not develop HCC over any single surveillance interval.

**HCC Surveillance Tests in At-Risk Patients**

If ultrasound-based surveillance is not possible for extended periods of time, blood-based biomarkers may be considered as an alternative strategy. Ultrasound with or without AFP achieve a sensitivity of ~63% for early HCC detection when used in combination, although performance may be lower in patients with NASH given increased concerns about poor ultrasound visualization.\textsuperscript{18,19} Although ultrasound is readily available in most areas, logistics of ultrasound-based surveillance, including need for a separate appointment, is a common patient-reported barrier to surveillance completion.\textsuperscript{20} This issue may be increasingly problematic in times where social distancing is recommended and patients are concerned about in-person visits. Given potential concerns about lack of social distancing between the ultrasound operator and patient, magnetic resonance–based surveillance could also be considered though this strategy is limited by cost-effectiveness when applied to broad populations of cirrhosis patients.

An alternative strategy which could mitigate some issues is blood-based biomarkers, as these can be done the same day as a clinic visit without a separate appointment. Although several serum-based biomarkers have been proposed, none except AFP have undergone phase III or IV validation in cohort studies.\textsuperscript{21} AFP has insufficient sensitivity and specificity to be used alone, although data suggest diagnostic performance is higher in patients with nonviral cirrhosis or HCV patients after virologic cure.\textsuperscript{22,23} Further, using longitudinal changes in AFP can increase accuracy for early HCC detection than single-threshold measurement at a cutoff of 20 ng/mL.\textsuperscript{24} Given similar concerns about insufficient accuracy for other single biomarkers, there has been increasing interest in biomarker panels. The best evaluated to date is GALAD, which combines gender, age, and 3 biomarkers—AFP, AFP-L3 (lectin-reactive alpha-fetoprotein), and DCP (des-gamma carboxyprothrombin). The panel has demonstrated sensitivities of 60%–80% for early-stage detection in large multinational case-control studies, including recent data among NASH patients.\textsuperscript{25,26,27} GALAD has shown superior performance to the component biomarkers, in part

| Professional society                                           | Guideline reference                                                                 | Description                                                                 |
|---------------------------------------------------------------|--------------------------------------------------------------------------------------|-----------------------------------------------------------------------------|
| American Association for Study of Liver Disease (AASLD)       | https://www.aasld.org/about-aasld/covid-19-resources                                 | COVID-19 Resources                                                          |
| American Society of Clinical Oncology (ASCO)                 | https://www.asco.org/asco-coronavirus-information/provider-practice-preparedness-covid-19 | Ethics and Resource Scarcity: ASCO Recommendations for the Oncology Community During the COVID-19 Pandemic\textsuperscript{76,79} |
| European Association for Study of the Liver (EASL)            | https://easl.eu/covid-19-and-the-liver/                                             | Care of Patients with Liver Disease during the COVID-19 Pandemic (EASL-ESCMID Position Paper)\textsuperscript{71} |
| European Society of Medical Oncology (ESMO)                  | https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic/gastrointestinal-cancers-hepatocellular-carcinoma-hcc-in-the-covid-19-era  | ESMO Management and Treatment Adapted Recommendations in the COVID-19 Era: HCC\textsuperscript{69} |
| International Liver Cancer Association (ILCA)                | https://ilca-online.org/management-of-hcc-during-covid-19-ilca-guidance/           | Management of HCC During COVID-19: ILCA Guidance\textsuperscript{74}         |
| National Comprehensive Cancer Network (NCCN)                 | https://www.nccn.org/covid-19/                                                      | Coronavirus Disease 2019 (COVID-19) Resources for the Cancer Care Community |

COVID-19, coronavirus disease 2019; HCC, hepatocellular carcinoma.

Table 1. Selected Professional Society Guidelines and Position Statements on Management of HCC During the COVID-19 Pandemic
| Author, year       | Components                                                                 | Derivation                                      | External validation | Link                                                                 |
|-------------------|-----------------------------------------------------------------------------|------------------------------------------------|---------------------|----------------------------------------------------------------------|
| Ioannou, 2019     | Age, gender, diabetes, body mass index, platelet count, serum albumin and aspartate aminotransferase-to-alanine aminotransferase ratio | 23,234 patients with NASH or alcohol-related cirrhosis; 1237 developed HCC | None                | https://www.journal-of-hepatology.eu/article/S0168-8278(19)30291-0/fulltext |
| Sharma, 2019      | Age, gender, etiology, platelet count                                        | 2079 patients with mixed etiologies of cirrhosis, 226 developed HCC | 1144 patients with mixed etiologies of cirrhosis, 107 developed HCC | https://www.journal-of-hepatology.eu/article/S0168-8278(17)32248-1/fulltext |
| Papatheodoridis, 2016 | Age, gender, platelet count                                                  | 1325 patients with chronic hepatitis B on entecavir/tenofovir, 51 developed HCC | 490 patients with chronic hepatitis B on entecavir/tenofovir, 34 developed HCC | https://www.journal-of-hepatology.eu/article/S0168-8278(15)00795-3/fulltext |
| Flemming, 2014     | Age, race, diabetes, etiology, gender, Child-Pugh score                     | 34,392 patients with mixed etiologies of cirrhosis, 1960 developed HCC | 426 patients with hepatitis C cirrhosis, 29 developed HCC | https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.28832 |
| Yang, 2011        | Sex, age, alanine aminotransferase, hepatitis B e antigen status, hepatitis B DNA | 3584 patients with chronic hepatitis B, 131 developed HCC | 1505 patients with chronic hepatitis B, 111 developed HCC | https://www.thelancet.com/journals/lancet/article/PIIS1470-2045(11)70077-8/fulltext |

HCC, hepatocellular carcinoma; NASH, nonalcoholic steatohepatitis.
related to inclusion of gender and age in the biomarker algorithm. Although this performance needs to be validated in cohort studies prior to routine use in clinical practice, blood-based biomarkers such as GALAD, AFP-adjusted algorithms, or longitudinal AFP may be a reasonable alternative if ultrasound-based surveillance cannot be easily performed for extended periods of time. Although unknown, surveillance intervals would likely be unchanged from ultrasound-based surveillance, as they are based on tumor doubling times and not test performance characteristics.

**Monitoring Patients after Potentially Curative HCC Therapy**

HCC patients with Barcelona Clinic Liver Cancer stage 0/A (single lesion or 2–3 lesions, each <3 cm) are typically treated with curative treatments including resection, ablation, or liver transplantation (LT); however, there is a persistent risk of recurrence after each treatment. Given that long-term survival can be achieved with early detection of HCC recurrence, ongoing HCC surveillance after curative therapy is recommended. Given higher HCC risk after curative therapy than in those with cirrhosis, surveillance is typically performed using cross-sectional imaging with multiphase abdominal computed tomography or contrast-enhanced magnetic resonance imaging with or without noncontrast chest computed tomography. After resection (or ablation), <25% of recurrences are extrahepatic, so the chest computed tomography can likely be forgone outside of situations such as rising AFP with negative abdominal imaging—particularly if this requires a separate visit and there is limited radiologic capacity.

### Timing of HCC Surveillance After Potentially Curative HCC Treatment

Similar to HCC surveillance among at-risk patients, surveillance after curative therapies for HCC has been associated with early stage detection and improved survival. While recurrence can be seen for up to 10 years following resection or LT, most recurrences occur within the first 2 years, so surveillance should be prioritized during this period. To determine appropriate posttreatment surveillance intervals, an estimation of individual recurrence risk should be undertaken. Multiple HCC recurrence risk scores that consider pathological analysis of the surgical specimen along with biomarkers (eg, AFP) have been established in the LT and resection population, although few have been validated. The

---

**Table 3. Approach to Surveillance After HCC Surgical and Local-Regional Treatments Under Normal Conditions and During COVID-19**

| HCC Treatment received | Surveillance recommendations under normal conditionsa | Surveillance recommendations during COVID-19a |
|------------------------|-----------------------------------------------|-----------------------------------------------|
| Liver transplantation   | No surveillance                              | No surveillance                               |
| 5-y recurrence risk     | Cross-sectional imaging of chest/abdomen + AFP| Cross-sectional imaging of chest/abdomen + AFP|
| Very low (<5%) (eg, RETREAT 0b) | Every 6 mo for 2 y                            | Every 6–8 mo for 2 y                          |
| Low (5%–15%)            | Every 6 mo for 5 y                            | Every 6–8 mo for 5 y                          |
| Moderate (15%–30%)      | Every 3–4 mo for 2 y then every 6 mo from years 2–5 | Every 3–6 mo for 2 y then every 6–8 mo from years 2–5 |
| High (>30%) (eg, RETREAT >5b) |Cross-sectional imaging of abdomen + AFP every 3–4 mo for 2 y then every 6 mo from years 2–5 | Cross-sectional imaging of abdomen + AFP every 3–4 mo for 2 y then every 6–8 mo from years 2–5 |
| Resection              | Cross-sectional imaging of abdomen + AFP every 3 mo for 2 y then every 4–6 mo from years 2–5 | Cross-sectional imaging of abdomen + AFP every 3–4 mo for 2 y then every 4–8 mo from years 2–5 |
| Ablation               | Cross-sectional imaging of abdomen + AFP every 3 mo for 2 y then every 4–6 mo from years 2–5 | Cross-sectional imaging of abdomen + AFP every 3–4 mo for 2 y then every 4–8 mo from years 2–5 |
| TACE                   | Cross-sectional imaging of abdomen + AFP every 4 weeks after TACE then every 3 mo (if no recurrent disease) | Cross-sectional imaging of abdomen + AFP every 3–4 mo for 2 y then every 4–8 mo from years 2–5 |
| Y-90 or SBRT           | Cross-sectional imaging of abdomen + AFP every 4 weeks after Y-90 or SBRT then every 3 mo (if no recurrent disease) | Cross-sectional imaging of abdomen + AFP every 3–4 mo for 2 y then every 4–8 mo from years 2–5 |

**AFP**: alpha-fetoprotein; COVID-19, coronavirus disease 2019; HCC, hepatocellular carcinoma; RETREAT, Risk Estimation of Tumor Recurrence After Transplant; SBRT, stereotactic body radiotherapy; TACE, transarterial chemoembolization.

*a* For HCC patients listed for liver transplantation, United Network for Organ Sharing requires cross-sectional imaging of abdomen + AFP at least every 3 months to maintain priority listing under normal conditions. During COVID-19, especially in patients at low risk for waitlist dropout, could consider extending this interval up to every 4–5 months.

*b* The RETREAT score incorporates 3 variables that independently predict HCC recurrence: microvascular invasion, AFP at liver transplantation, and the sum of the largest viable tumor diameter and number of viable tumors on explant.
Table 4. Serious Adverse Event Rates for Systemic Therapies and Strategies to Minimize COVID-19 Exposure Risk During a Pandemic

| Regimen                        | All-cause serious adverse events | Corticosteroid requirement | Strategies to minimize COVID-19 exposure risk |
|--------------------------------|----------------------------------|----------------------------|---------------------------------------------|
| **First-line options**         |                                  |                            |                                             |
| Atezolizumab plus bevacizumab   | 38.0%                            | NR                         | Consider alternate therapy in patients at risk for varices who require endoscopic surveillance; consider use of Baveno VI criteria for variceal assessment if elastography available. |
| Lenvatinib                     | 43%                              | NA                         | Consider remote safety monitoring:         |
| Sorafenib                      | 52%                              | NA                         | • Telemedicine visits                      |
| **Second- and later-line options** |                                  |                            |                                             |
| Regorafenib                    | 44%                              | NA                         | Can treat with extended dosing interval of 6 wk to reduce infusion center visit frequency if clinically appropriate; consider multikinase inhibitor if infusion center not accessible. |
| Cabozantinib                   | 50%                              | NA                         |                                             |
| Ramucirumab                    | 35%                              | NA                         |                                             |
| Nivolumab plus ipilimumab      | 22%<sup>a</sup>                  | 51%                        | Consider nivolumab monotherapy or multikinase inhibitor to minimize risk of immunosuppression and infection. |
| Nivolumab                      | 7%<sup>a</sup>                   | NR                         | Can treat with extended dosing interval of 6 wk to reduce infusion center visit frequency if clinically appropriate; consider multikinase inhibitor if infusion center not accessible. |
| Pembrolizumab                  | NR                               | 8.2%                       |                                             |

COVID-19, coronavirus disease 2019; NA, not applicable; NR, not reported.

<sup>a</sup>Reported only the rates of treatment-related rather than all-cause serious adverse events.

RETREAT (Risk Estimation of Tumor Recurrence After Transplant) score<sup>35,42</sup> is one validated risk stratification model that can be used to identify patients at highest risk of post-LT recurrence and who should be prioritized for surveillance in time of limited radiologic capacity. Patients with a RETREAT score of 0 have a <3% recurrence risk and likely do not benefit from surveillance. Likewise those with RETREAT scores of 1–3 can likely safely defer surveillance, particularly if beyond 2 years after LT. In contrast, those with RETREAT scores of ≥4 should likely continue at least semiannual surveillance until year 5 (Table 3).<sup>35</sup> In contrast, recurrence after resection and ablation is very common, and early detection is critical given the possibility of salvage transplant for those detected within Milan criteria.<sup>13,44</sup> Therefore, under normal circumstances, postresection or ablation surveillance should be performed approximately every 3–4 months for the first 2 years followed by every 4–6 months for years 2–5. In periods of limited radiologic capacity, it would be reasonable to extend each recommend interval by a short period (eg, extending 2–3 months), particularly in those with lower-risk features (eg, absence of poorly differentiated histology or microvascular invasion) and those more than 2 years beyond their treatment (Table 3).

**Monitoring HCC Patients Undergoing Local-Regional Treatment**

There is consensus that HCC patients should continue to receive local-regional therapy (LRT) during the COVID-19 pandemic, with choice of therapy discussed in a multidisciplinary format.<sup>45</sup> Risk of potential exposure versus presumed benefit of treatment should be discussed, with a lower threshold to delay palliative LRT procedures in elderly patients and in those with comorbidities.<sup>4</sup> COVID-19 testing should be performed approximately 48–72 hours prior to administering LRT. Factors specific to COVID-19 include local infection prevalence, infection risk after treatment, need for inpatient stay after LRT, use of general anesthesia, interventional radiology capacity, and hospital resources among others. For example, external stereotactic body radiotherapy (SBRT) typically involves multiple treatment sessions over several days, though it does not require postprocedure admission. Patients scheduled for Y-90 radioembolization commonly undergo angiography 1–2 weeks prior to treatment to evaluate for significant shunting that would make patients ineligible for Y-90 therapy. However, lung shunt fraction is negligible in early-stage patients receiving segmental Y-90 so this step may be eliminated,<sup>46</sup> which would reduce health care utilization and potential COVID-19 exposure. There is concern for serious COVID-19 infection in those receiving conventional transarterial chemoembolization (cTACE) (with cytotoxic agents) because of systemic absorption with increased myelosuppression, and therefore the International Liver Cancer Association recommends other forms of LRT over cTACE (eg, bland embolization, drug-eluting bead–TACE, Y-90).<sup>47</sup> Finally, consideration for earlier transition to systemic therapy could be considered in locally advanced HCC patients.<sup>17</sup>
Timing of HCC Surveillance to Assess Treatment Response After LRT

There is limited guidance about timing and follow up of post-LRT surveillance with wide variation in interventional radiology practices. Follow-up cross-sectional imaging should be performed approximately 4–6 weeks after TACE or ablation to assess response and determine need for repeat treatment (Table 3). In contrast, arterial enhancement and washout can persist for several months after radiation-based treatment (SBRT, Y-90), complicating radiologic interpretation within the first couple months. Therefore, especially during the COVID-19 pandemic, imaging after Y-90 or SBRT can likely be delayed and performed ~3–4 months after therapy (Table 3). AFP can also potentially be used as a marker for response to LRT, with imaging being delayed in patients with a significant drop in AFP from baseline (eg, >50%). Patients without viable disease after any form of LRT are recommended to undergo follow-up imaging every 3–4 months, although this also may be delayed in light of COVID-19 exposure risk, particularly for those with durable responses. In patients with worsening liver dysfunction, declining performance status, or other features that would preclude repeat treatment, imaging to assess response may also be deferred unless required for other reasons (eg, transplant eligibility).

HCC Monitoring in Patients Listed for Liver Transplant

Currently in the United States, HCC patients within Milan criteria currently receive MELD exception after a mandatory 6-month wait to facilitate LT. Centers for Medicare and Medicaid Services guidelines regarding surgery during the COVID-19 pandemics have categorized "transplant" as the highest priority. LT at some centers has been limited to the sickest (eg, acute liver failure, MELD ≥25), while less urgent cases are postponed because of limited resources with many living donor liver transplant programs being suspended. United Network for Organ Sharing recently announced policies to address changes during the COVID-19 pandemic to ensure that HCC patients will not be disadvantaged due to the national public health emergency. The policy now authorizes programs to "carry forward" clinical data and imaging from prior exception petitions, such as with HCC MELD exceptions, if obtaining updated data is not possible. However, it is important to obtain preoperative imaging at admission for LT if not done within the prior 3 months to ensure conventional LT criteria (ie, Milan) are still met.

In this climate, it is important to be able to risk stratify patients with HCC with moderate-to-high risk of waitlist dropout who will benefit from urgent LT during this period vs those with more indolent disease and a lower risk of dropout. Specifically, patients with a combination of favorable tumor characteristics (eg, single lesion <3 cm, AFP <20 ng/mL, complete response to LRT) and liver function (eg, CTP A cirrhosis and MELD score ≤13–15) appear to have a low risk of waitlist dropout. It would be appropriate to delay LT in such low-risk patients, given the lack of urgency and decreased LT survival benefit, and consider temporary inactivation.

Monitoring HCC Patients Undergoing Systemic Therapy

There are now multiple systemic therapies available for patients with advanced stages of HCC. In the first-line setting, treatment options include the multikinase inhibitors sorafenib and lenvatinib. The combination of atezolizumab, a monoclonal antibody targeting the PD-L1 (programmed death ligand 1), combined with bevacizumab, a monoclonal antibody targeting the vascular endothelial growth factor, has become a new standard for first-line therapy based on survival improvement over sorafenib. After progression on first-line therapy, treatment options depend on local regulatory approvals; in the United States, approved therapies include the multikinase inhibitors regorafenib and cabozantinib; a vascular endothelial growth factor monoclonal antibody, ramucirumab; and the immune checkpoint inhibitors nivolumab and pembrolizumab. Without established biomarkers beyond AFP, the choice of treatments in first- and later-line therapy depends on individual patient prognostic factors and an estimation of risk of adverse events from each therapeutic option. During the COVID-19 pandemic, local infection rates may influence systemic therapy risk assessment, monitoring capabilities, and choice of therapy.

The type of systemic therapy impacts the frequency and nature of monitoring required. For multikinase inhibitors with daily oral dosing, safety monitoring includes frequent blood pressure measurement, skin inspection (particularly of palms and soles for evolving palmar-plantar erythrodysesthesia findings), and laboratory testing of electrolytes and liver function. Rare but serious complications including hemorrhagic events and venous or arterial thromboembolism occur in a minority of patients. Safety monitoring on immune checkpoint inhibitor–based regimens, safety monitoring by laboratory testing and clinical encounters generally occurs at the same frequency as infusions, at intervals ranging from 2 to 6 weeks depending on agent and dosing regimen. Safety monitoring on immune checkpoint inhibitors requires vigilance for immune-related adverse events, which can range from more common events of mild rashes and arthralgias, to rare but potentially life-threatening events such as encephalitis, hypophysitis, myocarditis, pneumonitis, hepatitis, and colitis. Immune-mediated adverse events can evolve and progress rapidly and may require high doses of steroids, other immunosuppressive therapies, and hospitalization in severe cases.
In regions with high rates of COVID-19 transmission, safety monitoring via telemedicine may be an option for patients with access to technology. For patients treated with multikinase inhibitors, telemedicine monitoring requires patient or caregiver access and training on sphygmomanometry. Digital photographs of palms, soles, and any other areas of skin change can be uploaded to an electronic medical record for provider review. Laboratory tests can be performed at a local laboratory or, in some cases, via mobile phlebotomy, to minimize exposures to patient and health system. In patients treated with immune checkpoint inhibitors, regular visits to an infusion center remain necessary, along with laboratory monitoring. Patients and caregivers require education on the risks and warning symptoms of immune-related adverse events, which can require urgent medical evaluation.

Choice of Systemic Therapy in Advanced HCC

Regional COVID-19 exposure risk may impact choice of systemic therapy in advanced HCC based on availability of local resources (eg, infusion center, endoscopy, clinical trials) and risk of regimen-specific toxicities (eg, immune-related adverse events, which may require high doses of corticosteroids). Testing for active COVID-19 infection should be considered prior to initiation of therapies according to local institutional practice at the time of initiation, particularly for regimens with risk for immunosuppression. When considering first-line therapy options, the combination regimen of atezolizumab plus bevacizumab requires infusion of atezolizumab at 3-week intervals, along with a screening endoscopy within 6 months prior to treatment owing to risk of variceal hemorrhage associated with bevacizumab in prior phase 2 studies. If endoscopy or infusion center services are not available in a pandemic setting, an alternate first-line agent such as lenvatinib or sorafenib may offer a more favorable ratio of benefit to risk (Table 4). In the second-line and later treatment settings, the median durations of progression-free survival are longer, while rates of primary progressive disease are lower for the multikinase inhibitors regorafenib and cabozantinib compared with monotherapy with immune checkpoint inhibitors. These efficacy parameters along with oral dosing without infusion center requirement likewise may favor the choice of regorafenib or cabozantinib as second-line therapy in the context of a pandemic. Immune checkpoint inhibitor therapies, particularly in combinations such as the regimen of nivolumab plus ipilimumab, also confer a risk of immune-related complications requiring corticosteroid or other immunosuppression (Table 4), which may further increase COVID-19 transmission risk and severity. In regions with high rates of COVID-19 infection, an alternate regimen may be preferred.

Timing of HCC Surveillance to Assess Treatment Response With Systemic Therapy

For advanced HCC patients treated with systemic therapies, radiographic response is assessed using cross-sectional imaging of the chest, abdomen, and pelvis, usually within 3 months after treatment initiation. Though radiographic response is the gold standard for assessment of progression, continuation of treatment until symptomatic progression is an accepted practice for patients treated with multikinase inhibitors. In regions with high community COVID-19 transmission, extended imaging intervals may be appropriate in patients without symptomatic progression on systemic therapy. Beyond radiographic and clinical response assessment, serum AFP levels may also be a useful adjunct. Approximately 60%–80% of patients with advanced HCC have elevated AFP at start of systemic therapy. Changes in AFP on treatment have shown association with outcomes on multiple types of systemic therapies, including sorafenib, cabozantinib, and ramucirumab. Stabilization or decline in serum AFP on treatment, commonly defined as a decrease of at least 20%, has been shown to correlate with prolonged progression-free and overall survival, while increases in AFP correlate with poor outcomes. Though optimal thresholds of AFP response and progression require further validation, serum AFP kinetics offer an additional tool for response assessment (Figure 1) during the COVID-19 pandemic, when imaging may not be readily available and could confer additional risk of viral exposure.

Figure 1. Suggested algorithm for incorporation of serum AFP in systemic therapy response assessment during COVID-19 pandemic.
Conclusions

The COVID-19 pandemic has dramatically changed the delivery of health care worldwide. The resource-intensive management of patients with cirrhosis and HCC is particularly vulnerable to decreased health care resources during a pandemic. A principle of maximizing the risk-benefit ratio should be taken for the surveillance of HCC and monitoring of patients who have received therapies for HCC. Prioritizing imaging resources to those patients at highest risk will ensure a judicious strategy to risk stratifying these patients. For patients eligible for systemic therapy, the landscape is changing rapidly; however, the treatment regimen should be dictated by the risk of COVID-19 associated with route of administration, monitoring, and treatment of adverse events, within the context of relative efficacy for the treatment of HCC. These principles hold not only during times of active local transmission, but also in the post-pandemic period when prioritizing the backlog of patients in whom care was deferred due to limited health care resources. Patients at risk for and with HCC are among the highest-acuity patients as a whole, but allocating resources to those with the highest likelihood of benefit while minimizing exposure risk to COVID-19 is a prudent approach in a limited resource environment.

References

1. Tapper EB, Asrani SK. COVID-19 pandemic will have a long-lasting impact on the quality of cirrhosis care. J Hepatol 2020; 73:441–445.
2. Kissler SM, Tedijanto C, Goldstein E, et al. Projecting the transmission dynamics of SARS-CoV-2 through the post-pandemic period. Science 2020;368:860–868.
3. Boettler T, Newsome PN, Mondelli MU, et al. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. JHEP Rep 2020;2:100–113.
4. Iavarone M, Sangiovanni A, Carrafiello G, et al. Management of hepatocellular carcinoma in the time of COVID-19. Ann Oncol 2020 Apr 20 [E-pub ahead of print].
5. Ganne-Carrie N, Fontaine H, Dumortier J, et al. Suggestions for the care of patients with liver disease during Coronavirus 2019 pandemic. Clin Res Hepatol Gastroenterol 2020;44:275–281.
6. Denys A, Guîu B, Chevallier P, et al. Intervventional oncology at the time of COVID-19 pandemic. Diagn Interv Imaging 2020; 101:347–353.
7. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018;69:182–236.
8. Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 AASLD practice guidance. Hepatology 2018;68:723–750.
9. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130:417–422.
10. Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med 2014;11: e1001624.
11. Voulgaris T, Papatheodoridi M, Lampertico P, Papatheodoridis GV. Clinical utility of hepatocellular carcinoma risk scores in chronic hepatitis B. Liver Int 2020; 40:484–495.
12. Kanwal F, Kramer JR, Mapakshi S, et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. Gastroenterology 2018;155:1828–1837.
13. Farhang Zangneh H, Wong WWL, Sander B, et al. Cost effectiveness of hepatocellular carcinoma surveillance after SVR to therapy in patients with HCV infection and advanced fibrosis. Clin Gastroenterol Hepatol 2019; 17:1840–1849.e16.
14. Rich NE, John BV, Parikh ND, et al. Hepatocellular carcinoma demonstrates heterogeneous growth patterns in a multi-center cohort of patients with cirrhosis. Hepatology 2020 Feb 4 [E-pub ahead of print].
15. Nathani P, Gopal P, Rich N, et al. Hepatocellular carcinoma tumour volume doubling time: a systemic review and meta-analysis. Gut 2020 May 12 [E-pub ahead of print].
16. Trinchet JC, Chaffaut C, Bourcier V, et al. Ultrasoundographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology 2011;54:1987–1997.
17. Santi V, Trevisani F, Gramenzi A, et al. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol 2010; 53:291–297.
18. Tzartzeva K, Obi J, Rich NE, et al. Surveillance imaging and alpha-fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology 2018;154:1706–1718.e1.
19. Simmons O, Petzer DT, Yokoo T, et al. Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. Aliment Pharmacol Ther 2017; 45:169–177.
20. Farvardin S, Patel J, Khambaty M, et al. Patient-reported barriers are associated with lower hepatocellular carcinoma surveillance rates in patients with cirrhosis. Hepatology 2017; 65:875–884.
21. Pepe MS, Etzioni R, Feng Z, et al. Phases of biomarker development for early detection of hepatocellular carcinoma. J Natl Cancer Inst 2001; 93:1054–1061.
22. Gopal P, Yopp AC, Waljee AK, et al. Factors that affect accuracy of alpha-fetoprotein test in detection of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2014; 12:870–877.
23. Yang JD, Dai J, Singal AG, et al. Improved performance of serum alpha-fetoprotein for hepatocellular carcinoma diagnosis in HCV cirrhosis with normal ALT. Cancer Epidemiol Biomarkers Prev 2017;26:1085–1092.
24. Tayob N, Stingo F, Do KA, et al. A Bayesian screening approach for hepatocellular carcinoma using multiple longitudinal biomarkers. Biometrics 2018;74:249–259.
25. Berhane S, Toyoda H, Tada T, et al. Role of GALAD and BALAD-2 serologic models in diagnosis of hepatocellular carcinoma and prediction of survival in patients. Clin Gastroenterol Hepatol 2016;14:875–886.
26. Best J, Bechmann LP, Sowa JP, et al. GALAD score detects early hepatocellular carcinoma in an international cohort of patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2020;18:728–735.

27. Pinna AD, Yang T, Mazzaferrro V, et al. Liver transplantation and hepatic resection can achieve cure for hepatocellular carcinoma. Ann Surg 2018;268:868–875.

28. Mazzaferrro V, Sposito C, Zhou J, et al. Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma. Gastroenterology 2018;154:128–139.

29. Feng K, Yan J, Li X, et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol 2012;57:794–802.

30. Wang JH, Wang CC, Hung CH, et al. Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma. J Hepatol 2012;56:412–418.

31. Goldaracena N, Mehta N, Scalera I, et al. Multicenter validation of a score to predict prognosis after the development of HCC recurrence following liver transplantation. HPB (Oxford) 2019;21:731–738.

32. de Haas RJ, Lim C, Bhangui P, et al. Curative salvage liver transplantation in patients with cirrhosis and hepatocellular carcinoma. Hepatology 2018;67:204–215.

33. Chawla A, Ferrone C. Hepatocellular carcinoma surgical therapy: perspectives on current limits to resection. Chin Clin Oncol 2018;7:48.

34. Lee DD, Sapisochin G, Mehta N, et al. Surveillance for HCC after liver transplantation: increased monitoring may yield aggressive treatment options and improve postrecurrence survival. Transplantation 2020 Jan 13 [E-pub ahead of print].

35. Mehta N, Heimbach J, Harnois DM, et al. Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) score to predict hepatocellular carcinoma recurrence after liver transplant. JAMA Oncol 2017;3:493–500.

36. Roayaie S, Schwartz JD, Sung MW, et al. Recurrence of hepatocellular carcinoma after liver transplantation. Liver Transplant 2004;10:534–540.

37. Halazun KJ, Najjar M, Abdelmessih RM, et al. Recurrence after liver transplantation for hepatocellular carcinoma: a new MORAL to the story. Ann Surg 2017;265:557–564.

38. Agopian VG, Harlander-Locke M, Zarrinpar A, et al. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation. J Am Coll Surg 2015;220:416–427.

39. Chan AWH, Zhong J, Berhane S, et al. Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection. J Hepatol 2018;69:1284–1293.

40. Ang SF, Ng ES, Li H, et al. The Singapore Liver Cancer Recurrence (SLICER) Score for relapse prediction in patients with surgically resected hepatocellular carcinoma. PLoS One 2015;10:e0118658.

41. Xu XF, Xing H, Han J, et al. Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma. JAMA Surg 2019;154:209–217.

42. Mehta N, Dodge JL, Roberts JP, Yao FY. Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database. Am J Transplant 2018;18:1206–1213.

43. Lee SY, Konstantinidis IT, Eaton AA, et al. Predicting recurrence patterns after resection of hepatocellular cancer. HPB (Oxford) 2014;16:943–953.

44. Doyle A, Gorgen A, Muaddi H, et al. Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma <3 cm in potentially transplantable patients. J Hepatol 2019;70:866–873.

45. Fix OK, Hameed B, Fontana RJ, et al. Clinical best practice advice for hepatology and liver transplant providers during the COVID-19 pandemic: AASLD Expert Panel Consensus Statement. Hepatology 2020;72:287–304.

46. Gabr A, Ranganathan S, Mouli SK, et al. Streaming radioembolization in UNOS T1/T2 hepatocellular carcinoma by eliminating the lung shunt study. J Hepatol 2020;72:1151–1158.

47. Kudo M, Ueshima K, Chan S, et al. Lenvatinib as an initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and Child–Pugh A liver function. Cancers (Basel) 2019;11:1084.

48. Boas FE, Do B, Louie JD, et al. Optimal imaging surveillance schedules after liver-directed therapy for hepatocellular carcinoma. J Vasc Interv Radiol 2015;26:69–73.

49. Gaba RC, Baerlocher MO, Nikolic B, et al. Clinical and imaging follow-up practices after transarterial therapy for primary and secondary hepatic malignancies. Acad Radiol 2015;22:1510–1515.

50. Gaba RC, Lokken RP, Hickey RM, et al. Quality improvement guidelines for transarterial chemoembolization and embolization of hepatic malignancy. J Vasc Interv Radiol 2017;28:1210–1223.

51. Kimura T, Takahashi S, Takahashi I, et al. The time course of dynamic computed tomographic appearance of radiation injury to the cirrhotic liver following SBRT for hepatocellular carcinoma. PLoS One 2015;10:e0125231.

52. Atassi B, Bangash AK, Bahrami A, et al. Multimodality imaging following devi radioembolization: a comprehensive review and pictorial essay. Radiographics 2008;28:81–99.

53. Memon K, Kulik L, Lewandowski RJ, et al. Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies. J Hepatol 2012;56:1112–1120.

54. Centers for Medicare and Medicaid Services. Non-emergent, elective medical services, and treatment recommendations. Available at: https://www.cms.gov/les/document/cms-non-emergent-elective-medical-recommendations.pdf. Accessed May 6, 2020.

55. OPTN. Notice of emergency action. COVID-19 Emergency Policy Package. Available at: https://optn.transplant.hrsa.gov/media/3716/covid-19_emergency_policypackage_and_minibrief.pdf. Accessed May 6, 2020.

56. Mehta N, Dodge J, Hirose R, et al. Predictors of low risk for dropout from the liver transplant waiting list for hepatocellular carcinoma in long wait time regions. Am J Transplant 2019;19:2210–2218.

57. Lai Q, Vitale A, Iesari S, et al. Intention-to-treat survival benefit of liver transplantation in patients with hepatocellular cancer. Hepatology 2017;66:1910–1919.

58. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma. Lancet Oncol 2009;10:25–34.

59. Llovet JM, Ricci S, Mazzaferrro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378–390.

60. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma. Lancet 2018;391:1163–1173.
61. Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 2020; 382:1894–1905.

62. Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE). Lancet 2017;389:56–66.

63. Abou-Alfa GK, Borgen-Hagey AE, Kelley RK. Cabozantinib in Hepatocellular Carcinoma. N Engl J Med 2018;379:1384–1385.

64. Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2). Lancet Oncol 2019;20:282–296.

65. El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040). Lancet 2017;389:2492–2502.

66. El-Khoueiry A, Hsu C, Kang YK, et al. Safety profile of nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma in CheckMate 040. ILCA 2019. Available at: https://ilca-online.org/wp-content/uploads/2019/10/el-khoueiry_ilca_2019_cm040_oral_final_draft_20sep.pdf. Accessed May 6, 2020.

67. Finn RS, Ryoo BY, Merle P, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240. J Clin Oncol 2020;38:193–202.

68. El-Khoueiry A, Hsu C, Kang YK, et al. Safety profile of nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma in CheckMate 040. ILCA 2019. Available at: https://ilca-online.org/wp-content/uploads/2019/10/el-khoueiry_ilca_2019_cm040_oral_final_draft_20sep.pdf. Accessed May 6, 2020.

69. European Society for Medical Oncology. ESMO Management and Treatment Adapted Recommendations in the COVID-19 Era. Hepatocellular Carcinoma. 2020. Available at: https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic/gastrointestinal-cancers-hepatocellular-carcinoma-hcc-in-the-covid-19-era. Accessed May 6, 2020.

70. Sangro B, Chan SL, Meyer T, et al. Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. J Hepatol 2020;72:320–341.

71. European Society for Medical Oncology. ESMO Management and Treatment Adapted Recommendations in the COVID-19 Era. Hepatocellular Carcinoma. 2020. Available at: https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic/gastrointestinal-cancers-hepatocellular-carcinoma-hcc-in-the-covid-19-era. Accessed May 6, 2020.

72. Siegel AB, Cohen EI, Ocean A, et al. Phase II trial evaluating the clinical and biological effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008;26:2992–2998.

73. Benson AB 3rd, D’Angelica MI, Abbott DE, et al. NCCN Guidelines Insights: hepatobiliary cancers, version 1.2017. J Natl Compr Canc Netw 2017;15:563–573.

74. International Liver Cancer Association. Management of HCC During COVID-19: ILCA Guidance. 2020. Available at: https://ilca-online.org/management-of-hcc-during-covid-19-ilca-guidance/a. Accessed May 6, 2020.

75. Galle PR, Foerster F, Kudo M, et al. Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. Liver Int 2019;39:2214–2229.

76. Chau I, Park JO, Ryoo BY, et al. Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of phase 3 REACH study. Br J Cancer 2018;119:19–26.

77. He C, Peng W, Liu X, et al. Post-treatment alpha-fetoprotein response predicts prognosis of patients with hepatocellular carcinoma: a meta-analysis. Medicine 2019;98:e16557.

78. Zhu AX, Finn RS, Galle PR, Llovet JM, Kudo M. Ramucirumab in advanced hepatocellular carcinoma in REACH-2: the true value of alpha-fetoprotein. Lancet Oncol 2019;20:e191.

79. American Society of Clinical Oncology. COVID-19 Provider & Practice Information. 2020. Available at: https://www.asco.org/asco-coronavirus-information/provider-practice-preparedness-covid-19. Accessed May 6, 2020.

80. Ioannou GN, Green P, Kerr KF, Berry K. Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification. J Hepatol 2019; 71:523–533.

81. Sharma SA, Kowgier M, Hansen BE, et al. Toronto HCC risk index: a validated scoring system to predict 10-year HCC risk in patients with cirrhosis. J Hepatol 2017 Aug 24 [E-pub ahead of print].

82. Papatheodoridis G, Dalekos G, Sypsa V, et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol 2016;64:800–806.

83. Flemming JA, Yang JD, Vittinghoff E, et al. Risk prediction of hepatocellular carcinoma in patients with cirrhosis: the ADRESS-HCC risk model. Cancer 2014;120:3485–3493.

84. Yang HI, Yuen MF, Chan HL, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B). Lancet Oncol 2011;12:568–574.

85. Protopapas AA, Mylopoulou T, Papadopoulos VP, et al. Valuing and expanding the Baveno VI criteria for esophageal varices in patients with advanced liver disease. Ann Gastroenterol 2020;33:87–94.

Reprint Requests
Address reprint requests to: Neil Mehta, MD, UCSF, 513 Parnassus Avenue, Room S-357, San Francisco, California 94143. e-mail: neil.mehta@ucsf.edu; fax: (415) 476-0659.

Acknowledgments
The authors thank Mary Feng, MD (University of California, San Francisco); Ryan Gill, MD, PhD (University of California, San Francisco); Gabriel Schwartz, NP (University of California, San Francisco); Alan Venook, MD (University of California, San Francisco); Clifford Cho, MD (University of Michigan); Jorge Marrero, MD (UT Southwestern); and Arjmand Mufti, MD (UT Southwestern).

Conflicts of Interest
These authors disclose the following: Neil Mehta has served on advisory boards for Wako Diagnostics and has received institutional research funding from Wako Diagnostics, Glycotest, and Target Pharmasolutions. Neehar Parikh has served as a consultant for Bristol Myers-Squibb, Exact Sciences, Eli Lilly, and Freenome; has served on advisory boards for Genentech, Eisai, Bayer, Exelixis, and Wako Diagnostics; and has received institutional research funding from Bayer, Target Pharmasolutions, Exact Sciences, and Glycotest. R. Kate Kelley has served on advisory boards for Agios, AstraZeneca, Bristol Myers-Squibb, Genentech, and Gilead; and has received institutional research funding from Adaptennune, Agios, AstraZeneca, Bayer, Bristol Myers-Squibb, Eli Lilly, Exelixis, EMD Serono, Merck, Novartis, Partner Therapeutics, QED, and Taiho. Bilal Hamed has served on advisory boards for Surozen and Gilead; and has received institutional research funding from Gilead, Intercept, Conatus, Genfit, and Salix/Valeant. Amit Singal has served on advisory boards or as a consultant for Wako Diagnostics, Glycotest, Exact Sciences, GNAIl, Bayer, Eisai, Genentech, Exelixis, Bristol Myers-Squibb, and TARGET Pharmasolutions.